Abstract
Abstract: :
Purpose: To evaluate the efficacy, predictability, and safety of VISX CustomVue wavefront guided enhancement after previous keratorefractive surgery. Methods: Retrospective analysis was used to evaluate wavefront guided enhancement in a preliminary set of 35 eyes from 33 patients. All eyes had previously undergone keratorefractive surgery (PRK in 2 eyes, lasik in 33 eyes); the initial pre–keratorefractive surgery spherical equivalent refraction ranged form –1.25 to –7.00D. Primary outcome variables of UCVA, manifest refraction, and complications were evaluated at postoperative month 1 and 3. Results: At postoperative month 1, the mean pre–enhancement spherical equivalent was reduced from –0.88 ± 0.36D (range –1.875 to –0.25) to 0.066 ± 0.36D (range –0.5 to 0.75) with 89% of eyes within ± 0.5D of emmetropia and 100% within ± 0.75D of emmetropia. All eyes demonstrated equal or improved UCVA (range 20/15 to 20/30) with 20/20 or better in 22 out of 23 eyes. At postoperative month 3, the mean spherical equivalent was further reduced to 0.003 ± 0.36D (range –0.5 to 0.5) with 100% of eyes within ± 0.5D of emmetropia. Again, all eyes demonstrated equal or improved UCVA (range 20/15 to 20/20) with 20/20 or better in 10 out of 10 eyes. Higher order wavefront aberration analysis demonstrates that the mean rms error was reduced from .46 ± .14 (range .23 to .86) to .34 ± .09 (range .18 to .53). Conclusion: Preliminary data demonstrate that VISX CustomVue wavefront guided enhancement after previous keratorefractive surgery is an effective, predictable, and safe procedure.
Keywords: refractive surgery • refractive surgery: other technologies